Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06136351
Other study ID # ZBR-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 15, 2023
Est. completion date November 1, 2027

Study information

Verified date November 2023
Source Ruijin Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 23
Est. completion date November 1, 2027
Est. primary completion date November 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years - Histopathologically confirmed mantle cell lymphoma according to the 5th edition of the World Health Organization (WHO) - FISH with del(17p)/TP53 mutation or =65 years; or<65 years but chemotherapy intolerance; - Life expectancy of > 3 months (in the opinion of the investigator); - Creatinine Clearance Rate (CCR) = 50 mL/min or estimated Glomerular Filtration ?Rate (eGFR) = 60 mL/(minĀ·1.73 m^2); - International Normalized Ratio (INR) = 1.5 and activated Partial Thromboplastin Time (aPTT) = 1.5 times the upper limit of normal; - Left Ventricular Ejection Fraction (LVEF) = 50%; - Agreeing to provide written informed consent prior to any special examination or procedure for the research on their own or legal representative. Exclusion Criteria: - Pregnant or lactating women; - Known Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) infection (HBV infection refers to HBV-DNA > detectable limit); - With acquired or congenital immunodeficiency; - With congestive heart failure in 6 months before enrollment, New York Heart Association (NYHA) heart function class III or IV, or LVEF < 50%; - Known to be allergic to the test drug ingredients; - Diagnosed with or being treated for malignancy other than lymphoma; - With severe infection; - Substance abuse, medical, psychological, or social conditions that may interfere with the subjects' participation in the study or evaluation of the study results; - Deemed unsuitable for the group.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zanubrutinib
160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
Rituximab
375 mg/m^2 ivgtt, D0 of each 28-day cycle
Bendamustin
90mg/m^2 ivgtt, D0 of each 28-day cycle

Locations

Country Name City State
China Ruijin Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2-year Progression-Free Survival Progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of disease progression or relapse, according to 2014 Lugano criteria, or death from any cause, whichever occurred first. 2 years
Secondary ORR Objective Remission Rate (ORR) is defined as the proportion of patients with complete remission (CR) and partial remission (PR) End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]
Secondary CRR Complete Remission Rate (CRR) is defined as the proportion of patients with CR End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]
Secondary OS Overall survival (OS) refers to the time from receiving the first dose to death from any cause Baseline up to data cut-off (up to approximately 2 years)
Secondary Adverse Events Any harmful reaction that occurs during the treatment of a disease according to the normal usage and dosage of a drug, which is unrelated to the purpose of treatment. Baseline up to data cut-off (up to approximately 2 years)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03567876 - Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL Phase 2
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Not yet recruiting NCT04913103 - Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL Phase 2
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Terminated NCT02440685 - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00420056 - An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma. Phase 1
Completed NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Phase 2
Not yet recruiting NCT06427213 - This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04849416 - A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) Phase 2
Completed NCT03425591 - A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Completed NCT02257242 - Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma Phase 1
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Completed NCT00861510 - A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies Phase 1
Recruiting NCT04735471 - A Phase 1 Study of ADI-001 in B Cell Malignancies Phase 1
Withdrawn NCT05431179 - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Phase 3
Completed NCT02669017 - Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Phase 1
Terminated NCT00871546 - SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) Phase 2
Recruiting NCT03647124 - A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma